KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Botulinum Toxin Type A in the Treatment of Primary Axillary Hyperhidrosis:A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety in Chinese Patients.

Yiming Li, Baogang Sun, Jianyun Lu, Wei Lai, Huiping Wang, Qiuning Sun, Baoxi Wang, Yanyan Feng, Junfeng He, Yubao Huang, Yunkai Yang, Chengjun Zhang, Li Li

Aesthet Surg J 46(5) 520-529

PMID41553927
PMCIDPMC13064634
DOI10.1093/asj/sjaf260
发表日期2026-01-19
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:非 KM 图;Figure 3.:图注未提示 KM 曲线;Figure 4.:图注未提示 KM 曲线;Figure 5.:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: The efficacy and safety of botulinum toxin type A (BoNTA) treatment for primary axillary hyperhidrosis (PAH) have not been explored in the Chinese population. OBJECTIVES: The objective was to evaluate efficacy and safety of 1 intradermal BoNTA injection in Chinese PAH cases. METHODS: This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Patients were randomized to an experimental group or the control group at a ratio of 3:1 and received either BoNTA or a placebo once. The primary efficacy endpoint was the proportion of patients who experienced an over 50% reduction in axillary sweat weight at Week 4 posttreatment compared to baseline. The key secondary efficacy endpoints were the percentage changes in axillary sweat weight at Weeks 1, 4, 8, and 16 posttreatment. RESULTS: A total of 344 patients were randomized to the experimental group (n = 258) or the control group (n = 86). The proportions of patients who experienced an over 50% reduction in axillary sweat weight at Week 4 posttreatment were 83.72% (216/258) in the experimental group and 55.81% (48/86) in the control group, respectively. The between-group difference was 27.91% (P < .001). BoNTA treatment yielded a significant reduction in axillary sweat weight, hyperhidrotic area, hyperhidrosis disease severity scale (HDSS) scores, and grade of bromhidrosis. The patients in the experimental group reported significantly higher satisfaction scores than those in the control group. BoNTA treatment was well tolerated. Neither group experienced suspected unexpected serious adverse reactions, or adverse events or adverse drug reactions leading to withdrawal or death. CONCLUSIONS: One intradermal 50-U BoNTA treatment led to a significant reduction in axillary sweat weight, axillary hyperhidrotic area, HDSS scores, and axillary bromhidrosis grades in Chinese PAH patients. The therapeutic effect was maintained for 16 weeks posttreatment, with a favorable safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.The disposition of the patients.
非 KM Figure
Figure 2.Efficacy evaluations of the primary efficacy endpoint and partial secondary efficacy endpoints. (A) The proportions of patients who experienced over 50% reduction in axillary sweat weight at Week 4 posttreatment compared to baseline; (B) the percentage change in axillary sweat weight relative to baseline at Weeks 1, 4, 8, and 16 posttreatment; (C) the median duration of over 50% reduction in axillary sweat weight compared with baseline; (D) the satisfaction scores measured at Weeks 1, 4, 8, and 16 posttreatment.
非 KM Figure
Figure 3.Efficacy evaluations of HDSS scores and axillary hyperhidrotic area. (A) The proportion of patients with an improvement over 2 grades in HDSS scores at Weeks 1, 4, 8, and 16 posttreatment compared to baseline. (B) The changes in the axillary hyperhidrotic area compared with the baseline at 4, 8, and 16 weeks posttreatment. HDSS, hyperhidrosis disease severity scale.
非 KM Figure
Figure 4.In the treatment group, a 35-year-old female patient underwent intradermal injection of 50 U BoNTA per axilla. (A-H) Baseline and follow-up photographs of axillary hyperhidrotic areas. (A) Right axilla, baseline; (B) right axilla, 4 weeks posttreatment; (C) right axilla, 8 weeks posttreatment; (D) right axilla, 16 weeks posttreatment; (E) left axilla, baseline; (F) left axilla, 4 weeks posttreatment; (G) left axilla, 8 weeks posttreatment; (H) left axilla, 16 weeks posttreatment. In the control group, a 33-year-old female patient underwent intradermal injection of 50 U BoNTA placebo per axilla. (I-P) Baseline and follow-up photographs of axillary hyperhidrotic areas. (I) Right axilla, baseline; (J) right axilla, 4 weeks posttreatment; (K) right axilla, 8 weeks posttreatment; (L) right axilla, 16 weeks posttreatment; (M) left axilla, baseline; (N) left axilla, 4 weeks posttreatment; (O) left axilla, 8 weeks posttreatment; (P) left axilla, 16 weeks posttreatment. BoNTA, botulinum toxin type A.
非 KM Figure
Figure 5.Efficacy evaluations of axillary odor grades. (A) The relief rates at Weeks 1, 4, 8, and 16 posttreatment (patients with baseline axillary odor grades of 2 and 3). (B) The total response rates at Weeks 1, 4, 8, and 16 posttreatment (patients with baseline axillary odor grades of 2 and 3).
非 KM Figure